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Carbon monoxide (CO) can provide beneficial antiapoptotic
and anti-inflammatory effects in the context of
ischemia–reperfusion injury (IRI). Here we tested the ability
of pretreating the kidney donor with carbon monoxide-
releasing molecules (CORM) to prevent IRI in a transplant
model. Isogeneic Brown Norway donor rats were pretreated
with CORM-2 18h before kidney retrieval. The kidneys were
then cold-preserved for 26h and transplanted into Lewis
rat recipients that had undergone bilateral nephrectomy.
Allografts from Brown Norway to Lewis rats were also
performed after 6 h of cold ischemic time with low-dose
tacrolimus treatment. All recipients receiving CORM-2-treated
isografts survived the transplant process and had near-
normal serum creatinine levels, whereas all control animals
died of uremia by the third post-operative day. This beneficial
effect was also seen in isografted Lewis recipients receiving
kidneys perfused with CORM-3, indicating that CORMs have
direct effects on the kidney. Pretreatment of human umbilical
vein endothelial cells in culture with CORM-2 for 1 h
significantly reduced cytokine-induced nicotinamide
adenine dinucleotide phosphate-dependent production
of superoxide, activation of the inflammation-relevant
transcription factor nuclear factor-jB, upregulated
expression of E-selectin and intercellular adhesion
molecule-1 adhesion proteins, and leukocyte adhesion
to the endothelial cells. Thus, CORM-2-derived CO protects
renal transplants from IRI by modulating inflammation.
Kidney International (2011) 79, 1080–1089; doi:10.1038/ki.2010.542;
published online 26 January 2011
KEYWORDS: carbon monoxide; ischemia–reperfusion injury;
kidney transplant
Kidney transplantation remains the best option for patients
suffering from end-stage renal disease.1 Over the last two
decades, dramatically improved short-term outcomes follow-
ing kidney transplantation have occurred.2 Nevertheless,
long-term graft survival and allograft half-life has failed to
improve substantially during this period of time.3–6 It is likely
that the limited improvements in allograft survival are related
with the ongoing damage incurred by ischemia–reperfusion
injury (IRI) as a result of prolonged preservation and organ
revascularization. IRI has been shown to result in irreversible
organ damage and has been speculated to participate in the
chronic development of interstitial fibrosis and tubular
atrophy. Unfortunately, effective strategies to prevent inter-
stitial fibrosis and tubular atrophy have yet to be identified.
Evidence indicates that carbon monoxide (CO) can provide
beneficial antiapoptotic and anti-inflammatory effects in the
context of IRI.7 During IRI, endogenous CO is generated from
heme degradation through heme oxygenase-1 activity.8 This
pathway has been identified as a natural powerful cytoprotec-
tive mechanism.9 More recently, low-dose exogenous CO has
been studied in numerous transplant models, including
kidney10–14 liver,15,16 intestine,17,18 lung,19–22 and heart,23 with
promising results. However, exogenous CO administration
has been shown to increase carboxyhemoglobin (COHb),
with the theoretical risk of impaired oxygen delivery to
organs and tissues.16,24 To circumvent this problem, novel
CO-releasing molecules (CORMs) have been created to
deliver consistent amounts of CO to tissues without a
significant impact on COHb levels. CORMs have been shown
to counteract numerous inflammatory conditions such as
sepsis25–29 and coronary ischemia.30,31 A few publications
have also reported interesting results in renal IRI32 and
transplantation models.33–35 Thus far, CORM has yet to have
been used in in vivo kidney transplant studies. Therefore,
we hypothesized that CORM would prevent inflammation
in transplant-relevant models of cellular injury. Specifically,
we hypothesized that CORM could protect the kidney against
IRI in a kidney transplant model.
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RESULTS
Effects of CORM-2 donor preconditioning on graft
function/morphology and survival following isogeneic
transplantation
Donor rats were pretreated with 8 mg/kg intraperitoneal (IP)
CORM-2 18 h before procurement and transplanted into
isogeneic Lewis rats. Control rat donors were pretreated with
(a) saline, (b) dimethyl sulfoxide (DMSO; used to dissolve
CORM), (c) iCORM (inactivated CORM), or (d) CORM-2
plus soluble guanylate cyclase (sGC) inhibitor, ODQ. As
shown in Figure 1a, recipients receiving the CORM-2-treated
grafts were the only ones to survive the transplant process.
In parallel, preconditioning of donor animals with
CORM-2 resulted in abrogation of IRI with respect to the
decreased serum levels of creatinine. As shown in Figure 1b,
serum creatinine levels in CORM-2-treated animals were
significantly lower as compared with all other control groups
(except untransplanted normal animals) on post-operative
day 3. Interestingly, ODQ pretreatment before CORM-2
donor preconditioning abrogated the protective effect of
CORM-2, indicating that activation of sGC is critical to the
protective mechanism of CORM-2.
The histological analysis (light microscopy) of the
isografts demonstrated that CORM-2-treated kidneys had
reduced damage versus all other groups on post-operative
day 2 (Figure 1c). Assessment of damage using an IRI severity
score derived by pathologists blinded to the treatment groups
indicated that control kidneys (iCORM-2, CORM-2þODQ,
and DMSO treatment) sectioned on day 2 sustained severe
acute tubular injury (grade 2–3 injury); however, CORM-2-
treated animals sustained far less injury (grade 0–1;
Figure 1d). No differences were seen regarding monocyte or
neutrophil infiltration of the interstitium.
Effects of CORM-2 donor preconditioning on graft
function/morphology and survival following allogeneic
transplantation
Brown Norway rats were pretreated with 8 mg/kg IP
CORM-2 18 h before procurement and transplanted into
allogeneic Lewis rats after a 6-h cold ischemic time. A
reduced ischemic time was used as the synergistic stresses of
allotransplantation and 26 h ischemia prevented long-term
survival in animals (data not shown). Without immuno-
therapy, animals died within 3 days from uremia (creatinine
780±150 mmol/l) using this transplant model. In our
experiment, a low dose of tacrolimus (0.2 mg/kg intra-
venously) was given to allograft recipients post-operatively.
Control allografted animals did not receive CORM-2
infusion. None of the control animals survived beyond
12 days (mean 11.0 days), and recipients had inferior graft
function versus CORM-2-treated animals at 7 days. Excellent
graft function was noted on day 70 in CORM-2-treated
animals (creatinine 52±9 mmol/l). Accordingly, histological
examination on day 10 showed lymphocytic infiltrate, glome-
rular congestion, and acute tubular necrosis in controls,
whereas CORM-2-treated animals had completely normal
histology on day 10 (Figure 2c). By day 70, CORM-2-treated
animals demonstrated vascular lymphocytic infiltrates and
glomerular atrophy, despite having excellent renal function
(not shown). This indicates that CORM-2 preconditioning
has profound effects on allogeneic transplantation associated
with reduction of inflammation and damage.
Effects of direct CORM-3 perfusion on graft function/
morphology and survival following isogeneic transplantation
After procurement from Lewis rats, kidneys were perfused
with 100 mmol/l CORM-3 in University of Wisconsin
solution (UW) and stored for 26 h before transplantation
into Lewis recipients. CORM-3 was used in these experi-
ments as DMSO solvent for CORM-2 was found to be
directly toxic to tubular epithelial cells and attenuated graft
survival (data not shown). Control kidneys were perfused
and stored in UW solution for 26 h. Figure 3a demonstrates
that none of the control animals survived the transplant
process, whereas dramatically improved survival was seen
in the CORM-treated animals (Po0.05). Similarly, renal
function on day 3 was superior in the CORM-treated
group versus control (Figure 3b), as was the renal histology
(Figure 3c). CORM-3 perfusion was associated with reduced
tubular necrosis (grade 0 versus 2) and glomerular necrosis
(grade 0 versus 2) compared with control. These data
indicate that CORM directly affects transplanted tissues.
Effects of CORM-2 pretreatment on modulation of
inflammatory responses in cytokine-stimulated endothelial
cells
It has been demonstrated that interventions/pathologies
associated with the organ/tissue ischemia/reperfusion (organ
transplantation) results in a marked increase in the levels of
circulating proinflammatory cytokines (for example, tumor
necrosis factor (TNF)-a and interferon-g), which have a key
role in activation (for example, reactive oxygen species (ROS)
production) of vascular endothelium and subsequent upre-
gulation of the proadhesive endothelial phenotype. This
inevitably leads to the overwhelming inflammatory cell (for
example, polymorphonuclear (PMN)) recruitment to the
afflicted sites, resulting in organ/tissue oxidative/proteolytic
damage and impaired function.36
Therefore, in the next series of experiments, we assessed
the effect of CORM-2 on intracellular ROS production,
activation of inflammation-relevant transcription factor,
nuclear factor (NF)-kB, expression of adhesion molecules
E-selectin, and intercellular adhesion molecule (ICAM)-1 in
cytokine-stimulated vascular endothelial cells. As a functional
correlate, PMN adhesion to endothelial cells was also
assessed.
To assess the effects of CORM-2-derived CO in modu-
lation of intracellular oxidative stress, human umbilical vein
endothelial cells (HUVECs) were treated with CORM-2,
DMSO, iCORM-2, or with sGC inhibitor, ODQ, before
CORM-2 treatment. HUVECs were stimulated with TNF-a/
interferon-g mixture at equimolar concentrations, and the
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Figure 1 | Effect of carbon monoxide-releasing molecule (CORM)-2 donor preconditioning on isogeneic transplantation. Donor
preconditioning with CORM-2 (8mg/kg, intraperitoneal (IP)) 18 h before kidney procurement provided significant recipient protection
against ischemia–reperfusion injury (IRI) based on (a) survival (CORM-2 (N¼ 6), dimethyl sulfoxide (DMSO; N¼ 3), untreated (N¼ 3),
inactivated CORM (iCORM-2; N¼ 3), and CORM-2þODQ (N¼ 2) groups shown) with (b) graft function on day 2, (c) histopathology on day 2,
and (d) corresponding pathology scores following isogeneic transplant after 26-h cold storage. This protective effect seems to be provided
by CORM-2 released CO, as inactivated CORM-2 did not prevent IRI. Note that severe acute tubular necrosis and hemorrhage was
demonstrated in each group, except for the CORM-2-treated group (mild acute tubular necrosis). Black arrows point to areas of
hemorrhage. Original magnification  400 Furthermore, abrogation of transplant-related injury seems to be mediated through the cyclic
3’,5’ guanosine monophosphate pathway, as the effect is totally abolished by pretreatment with an inhibitor of soluble guanylate cyclase,
ODQ (5mg/kg, IP), injected 1 h before CORM-2 preconditioning. Values are mean±s.e.m. *Po0.005 compared with all other groups.
Note that the number of CORM-treated animals in the survival experiment (N¼ 6) differs from the pathology score experiment (N¼ 4),
as a separate set of treated animals were utilized in order to obtain renal histology on day 2.
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lucigenin assay was used to measure nicotinamide adenine
dinucleotide phosphate (NADPH)-dependent production of
O2
. As shown in Figure 4, stimulation of HUVEC with TNF-
a/interferon-g markedly increased NADPH-dependent pro-
duction of O2
. The latter effect was effectively suppressed in
CORM-2 (but not in iCORM-2)-pretreated cells. Treating
HUVECs with CORM-2 or iCORM-2 in the absence of
cytokine stimulation had no effect on ROS production.
Interestingly, pretreating HUVECs with ODQ did not abolish
CORM-2 effects, as seen in the in vivo experiments. These
results suggest that in the system consisting with a single cell
type (i.e. endothelial cells) the protective effects of CORM-2
with respect to cytokine-induced NADPH-dependent pro-
duction of O2
 are sGC-independent.
It has been demonstrated that increased production of
ROS leads to activation of inflammation-relevant trans-
cription factor, NF-kB.37 Therefore, in the next series of
experiments we assessed the effects of CORM-2 pretreatment
on modulation of NF-kB activation in TNF-a/INF-g-
stimulated HUVECs. As shown in Figure 5, stimulation of
HUVECs with TNF-a/INF-g resulted in an induction of
NF-kB activation as assessed by degradation of NF-kB inhi-
bitory protein, IkB (inhibitory protein k-B). Pretreatment of
HUVECs with CORM-2 was effective in preventing cytokine
stimulation-induced IkB degradation. As in the previous
experiments (see Figure 4), interfering with sGC activity by
ODQ failed to prevent the protective effects of CORM-2.
Regulation of the vascular proadhesive phenotype is
tightly controlled by NF-kB.37 Therefore in the next
series of experiments, we assessed the effects of CORM-2
pretreatment on potential modulation of NF-kB-dependent
expression of adhesion molecules, E-selectin and ICAM-1,
in response to stimulation of HUVECs with the cyto-
kine mixture. As shown in Figure 6, CORM-2 but not its
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Figure 2 | Effect of carbon monoxide-releasing molecule (CORM)-2 donor preconditioning on allograft transplantation. Donor
preconditioning with CORM-2 (8mg/kg, intraperitoneal) 18 h before kidney procurement provided significant recipient protection against
ischemia–reperfusion injury based on (a) survival (CORM-2, untreated) with (b) graft function on day 7, and (c) histopathology after
allotransplantation (Brown Norway-Lewis). After University of Wisconsin solution (UW) flush and 6 h storage in UW solution, grafts failed
within 3 days with corresponding histopathological features of interstitial hemorrhage and glomerular and tubular necrosis (arrows) mixed
with lymphocytic infiltration if no immunotherapy was given. Animals treated with tacrolimus had glomerular congestion and tubular
necrosis with lymphocytic infiltrates by day 10. In contrast, if donors were pretreated with CORM-2, tacrolimus-treated animals had superior
renal function and survival, with corresponding normal histology on day 10. POD, post-operative day. Original magnification  400. Values
are mean±s.e.m. *Po0.001.
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inactive counterpart, iCORM-2, was effective in reducing
E-selectin and ICAM-1 expression in TNF-a/INF-g-stimulated
HUVECs, as assessed at the transcription level (reverse
transcription-polymerase chain reaction (PCR); Figure 6).
The latter changes were accompanied by CORM-2-dependent
attenuation of PMN adhesion to TNF-a/INF-g-stimulated
HUVECs (Figure 7).
DISCUSSION
Although hormonal manipulation of the deceased organ
donor has led to increased viable organs during the
procurement procedure,38 few donor-directed strategies have
been used to prevent organ damage. Recently, CO has been
shown to have anti-inflammatory effects,7 and administra-
tion of inhaled CO protected rat organs from transplant-
related injury.10–23 Unfortunately, the prospect of using
inhaled CO in clinical transplantation is limited due to
difficulty in CO storage and delivery in a controlled manner.
As well, CO binds to hemoglobin and forms COHb with an
affinity 240 times higher than that of oxygen, interfering with
oxygen transport and delivery to the organs/tissues with
potentially life-threatening consequences.16,24
Recently, the availability of CORM capable of releasing CO
in biological systems in a controlled manner provides the
opportunity to investigate CO-mediated biological effects
in more detail.39 On a separate note, it is worthwhile to
mention that while both routes of CO administration (that is,
by inhalation or systemic administration) exhibit anti-
inflammatory effects, the use of CO donors in vivo does
not result in a dramatic increase in COHb levels, as opposed
to inhaled CO.39–41 In this regard, it has been recently shown
that inhaled CO (20 p.p.m.) increased COHb levels from 1 to
10% in experiments performed on rats,14 whereas no
significant changes in %COHb levels were found in animals
treated with CO donor, CORM-3.32 The levels of COHb in
our current study using CORM therapy were consistently
below 3% (data not shown). The latter COHb levels are
significantly lower than the ones associated with light
cigarette smoking.42
In the current study, we used a CO donor, CORM-2, that
is lipid (DMSO)-soluble and reversibly releases CO by the
ruthenium metal center after ligand substitution with DMSO.
Therefore, initial experiments were carried out using DMSO-
treated controls along with conventional control groups.
However, in order to successfully carryout experiments
involving direct perfusion of kidney tissues without causing
DMSO-related damage, a second water-soluble CORM with a
ruthenium metal center (CORM-3) was utilized.39,43
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Figure 3 | Effect of perfusate-based carbon monoxide-releasing molecule (CORM)-3 flush on isogeneic transplantation. Lewis
isogeneic renal transplants were performed. After procurement of kidneys, the isografts were flushed with 1ml of 100 mmol/l CORM-3
or University of Wisconsin solution (UW) control, and stored for 26 h. Results were analyzed for (a) survival, (b) renal function on day 3,
and (c) histopathology on day 3 after transplantation. Greater degree of tubular and glomerular necrosis (arrows) was seen in the
UW-treated animals versus CORM. Original magnification  400. Values are mean±s.e.m. *Po0.01.
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Previous studies in the field indicate that, when adminis-
tered directly to the kidney, CORM contribute to vaso-
dilation and improved renal perfusion and glomerular
filtration rate.32–35 Herein, we have shown for the first time
that CORM administered to the organ donor can improve
renal transplant survival, and function, with corresponding
protection against histological damage after prolonged cold
storage in a transplant model. In our isogeneic transplant
model, this resulted in reduced tubular and glomerular
damage during a 26-h cold ischemic time. Compared with
the isogeneic model, pretreatment of the allograft donor with
CORM also resulted in similar protection in graft survival
and function. Additionally, marked reduction of inflamma-
tion was also noted, with complete absence of lymphocytic
infiltration versus control by day 10. This has profound
immunological implications regarding development of rejec-
tion, and therefore, ongoing chronic allograft damage.
Furthermore, we have shown that direct infusion of CORM
into the renal isograft preserves renal function, survival, as
well as histology. This indicates that in addition to its
systemic effects, CORM directly protects transplanted tissues
during the ischemic phase of cold storage.44 It is also likely
that CORM directly prime endothelial cells against reper-
fusion injury as well. Using transplant-relevant models with
cytokine-induced stress, we have now shown that CORM
prevents neutrophil to endothelial cell adhesion in associa-
tion with reduction of NADPH-dependent production of
O2
, reduced activation of inflammation-relevant transcrip-
tion factor NF-kB, and subsequent expression of adhesion
molecules E-selectin and ICAM-1.
Moreover, the results of this study indicate that protective
effects of CORM-2-derived CO in our in vivo experiments
are mediated through sGC-dependent signaling. When sGC
inhibitor ODQ was given to the donor animals before
CORM-2 therapy, abrogation of the beneficial effects of
CORM-2 on graft survival, function, and histology was
noted. However, although there were trends showing mild
attenuation of inflammation, it is important to note that
ODQ was unable to completely inhibit the effects of
CORM-2 on endothelial cell inflammation in our in vitro
studies. This indicates that the GC/cyclic 3’,5’ guanosine
monophosphate pathway may not be completely responsible
for direct and local anti-inflammatory effects of CORM-2 at a
single cell level, but may have a central role in more complex
systems that involve multiple cell types and paracellular
interaction between those cells during IRI.
Despite the obvious protective/anti-inflammatory effects
of CO in both, in vivo and in vitro experimental settings, the
exact mechanism(s) of CO action are poorly understood.43
CO can directly or indirectly influence the outcome of
numerous physiological/pathological processes in almost all
tissues/organs investigated.45 The latter scenario emphasizes
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Figure 4 | Effect of carbon monoxide-releasing molecule
(CORM)-2 on intracellular production of reactive oxygen
species (ROS) in cytokine-stimulated human umbilical vein
endothelial cell (HUVECs). HUVECs were grown to confluence in
six-well cell culture plates. They were pretreated with ODQ
(10mmol/l) for 30min when it applies, then treated with CORM-2
(100mmol/l), or an equivalent (dimethyl sulfoxide (DMSO),
inactivated CORM-2) for 1 h. Subsequently, HUVECs were
stimulated with cytokines (tumor necrosis factor-a (10 ng/ml) and
interferon-g (10 ng/ml)) for 1 h. Lysed and sonicated cells were
used to perform the lucigenin assay and measure intracellular
production of ROS. Values are mean±s.e.m. n¼ 4 in triplicate. No
statistical difference between non-stimulated control and other
non-stimulated groups.*Po0.01 compared with unstimulated
control; #Po0.001 compared with cytokine-stimulated control;
wPo0.05 compared with their unstimulated counterpart.
RLU, relative chemiluminescence (light) unit.
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Figure 5 | Stimulation of human umbilical vein endothelial cell
(HUVECs) with cytokines results in nuclear factor (NF)-jB
upregulation. Activation of NF-kB was assessed by the means of
degradation of its inhibitory protein kB (IkB). To this end, HUVECs
grown in six-well cell culture plates were washed following
various experimental treatments with phosphate-buffered saline
containing protease inhibitors and lysed in a hot electrophoresis
sample-loading buffer. Sample protein concentration was
determined using detergent-compatible protein assay. After
electrophoresis, lysates interacted with rabbit anti-IkB antibody.
*Po0.05 versus unstimulated group. #Po0.05 versus stimulated
group. CORM, carbon monoxide-releasing molecule; INF-g,
interferon; iCORM, inactivated CORM; TNF-a, tumor necrosis
factor-a.
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the pleiotropic effects of CO and indicates the potential
existence of multiple mechanisms associated with CO-
dependent modulation of inflammation. In regard to the
latter, it appears that CO, when applied at low concentra-
tions, can modulate several signaling pathways in cultured
cells, including those regulated by sGC and/or involving
mitogen-activated protein kinases (MAPKs).46
However, the integration of sGC/MAPK pathway appears
to be cell type-specific.47 Previous studies indicate that
CO inhibits smooth muscle cell proliferation by activation of
sGC and downstream activation of p38 MAPK,48 whereas
CO-dependent inhibition of the proinflammatory response
in lipopolysaccharide-stimulated macrophage-like cells
appears to be sGC-independent and involves activation of
p38 MAPK-dependent signaling.49 Therefore, it appears that
the overall beneficial effects of CO are achieved through a
multilateral, and sometimes overlapping, signaling pathways,
which appear to be cell type-specific and dependent on the
experimental model employed.
In summary, we have shown for the first time that
CORM can protect the kidney transplant from IRI and
improve early graft function and survival. It appears that
CO-induced graft protection occurs through the cGC/
cGMP pathway at the whole organ level. The ability of
CORM-derived CO to suppress vascular endothelial cell
proadhesive phenotype may further contribute to the overall
reduced organ injury/dysfunction following transplantation
of CO-pretreated kidney.
MATERIALS AND METHODS
Animals
Adult Brown Norway and Lewis rats weighing 250–300 g
were obtained from Charles-River Laboratory (Bar Harbor,
ME) and maintained in the animal facility of the University
of Western Ontario. Animal experiments were conducted
in accordance with the Canadian Council on Animal Care
guidelines under protocols approved by the Animal Use
Subcommittee at our institution. Animals were housed in
conventional conditions and with free access to food and
water.
Renal transplant model
Anesthesia was induced using intramuscular rhombine
(0.04 mg/kg intramuscular) and ketamine (0.1 mg/kg intra-
muscular), and animals were maintained with 2% isoflurane
in oxygen via facemask. Animals were kept on a warming
blanket during the entire surgical procedure. Left renal
transplantations were performed as previously described.50
Briefly, renal iso/allografts were procured in a standard
fashion and cold-preserved in UW solution for either 6 or
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Figure 6 | Effect of carbon monoxide-releasing molecule
(CORM)-2 on expression of adhesion molecules (intercellular
adhesion molecule (ICAM)-1 and E-selectin) in cytokine-
stimulated human umbilical vein endothelial cells (HUVECs).
HUVECs were grown to confluence in six-well cell culture plates.
They were pretreated with ODQ (10mmol/l) for 30min when it
applies, then treated with CORM-2 (100 mmol/l) or an equivalent
(dimethyl sulfoxide (DMSO), inactivated CORM-2) for 1 h.
Subsequently, HUVECs were stimulated with cytokines (tumor
necrosis factor-a (10 ng/ml) and interferon-g (10 ng/ml)) for 2 h.
RNA was extracted and adhesion molecule expression was
assessed with reverse transcription-PCR for ICAM-1 and E-selectin
following cytokine stimulation. Values are mean±s.e.m. n¼ 3 in
triplicate. No statistical difference was noted between non-
stimulated control and other non-stimulated groups.*Po0.001
compared with unstimulated DMSO group; #Po0.01 compared
with cytokine-stimulated DMSO group.
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Figure 7 | Effect of carbon monoxide-releasing molecule
(CORM)-2 on neutrophil adhesion in cytokine-stimulated
human umbilical vein endothelial cells (HUVECs). HUVECs
were grown to confluence in 48-well cell culture plates. They were
pretreated with ODQ (10 mmol/l) for 30min when it applies, then
treated with CORM-2 (100 mmol/l) or control (dimethyl sulfoxide
(DMSO), inactivated CORM-2) for 1 h. Subsequently, HUVECs were
stimulated with cytokines (tumor necrosis factor-a (10 ng/ml) and
interferon-g (10 ng/ml)) for 4 h. Human neutrophils were isolated,
labeled with Cr51, and incubated (3 106/well) with HUVECs for
1 h. Subsequently, percentage of adherent neutrophils was
quantified. Values are mean±s.e.m. n¼ 6 in triplicate. No
statistical difference between unstimulated control and other
unstimulated groups. *Po0.05 compared with unstimulated
control; #Po0.05 compared with cytokine-stimulated control;
wPo0.05 compared with their unstimulated counterpart. PMN,
polymorphonuclear.
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26 h. After bilateral recipient nephrectomies, the graft was
revascularized with end-to-side anastomoses between the
donor renal artery and recipient abdominal aorta and the
donor renal vein and recipient inferior vena cava. Subse-
quently, an end-to-end ureteric anastomosis was fashioned.
Experimental groups and survival protocol
In the experiments involving pretreatment of donors with
CORM-2, rat donors (n¼ 2–6 per group) were allocated
to one of the five following groups: (1) CORM-2 treated
(8 mg/kg, IP, given 18 h before organ procurement), (2)
vehicle treated (0.25% DMSO in saline, IP, given 18 h before
organ procurement), (3) normal saline treated (IP, given
18 h before organ procurement), (4) inactivated CORM-2
(8 mg/kg, IP, given 18 h before organ procurement), and (5)
ODQ treated (5 mg/kg, IP, given 1 h before CORM-2 injection)
followed by CORM-2 (8 mg/kg, IP, given 18 h before organ
procurement). This 18 h time point was chosen according to
successful preconditioning studies performed by others.32
All compounds were injected using a total volume of
1.0-ml normal saline. Two subsets of the animals were
killed at 72 h and 10 days post-transplant (for histological
analysis), while another subgroup was survived until study
termination.
In the experiments involving graft perfusion with
CORM-3, grafts were flushed with 1 ml of 100 mmol/l
CORM-3 dissolved in UW solution or flushed with UW by
itself (control) directly following procurement.
Analysis of renal function
Serum creatinine levels were used for evaluation of renal
function after IRI. Blood samples were collected at 24 and 72 h
post-reperfusion. Serum creatinine was measured by colori-
metric enzymatic means by the Roche Modular Analyzer
(Hoffmann-La Roche, Mississauga, ON, Canada).
Histopathological and morphometric analysis
At necropsy, allografts were removed, fixed in 10% buffered
formaldehyde and embedded in paraffin. They were then
sectioned for hematoxylin–eosin staining. The sections were
graded by two blinded experienced pathologist (BG and FS)
and graded for severity of injury to the kidney as follows: 0,
normal; 1, minimal change; 2, mild change; 3, moderate
change; 4, marked change. The entire outer renal cortex and
medulla were assessed for these changes.
Endothelial cells
HUVECs were prepared from fresh umbilical cords by
collagenase treatment (Sigma, Oakville, ON, Canada) as
previously described.29 The cells were cultured in 25-cm2
flasks that had been coated with fibronectin (10 mg/ml,
Sigma). The culture medium consisted of M199 (Sigma)
supplemented with 10% heat-inactivated fetal calf serum
(Wisent, St Bruno, Quebec, Canada), heparin sodium
(10 IU/ml, PPC, Richmond Hill, ON, Canada), penicillin
(100 IU/ml)–streptomycin (100mg/ml) (Wisent) and endothelial
cell mitogen (100 mg/ml, Biomedical Technologies, Stought-
on, MA). The cultures were incubated at room air with
5% CO2, 37 1C and 95% humidity and expanded by brief
trypsinization with 0.25% trypsin in phosphate-buffered
saline (PBS) containing 0.025% EDTA (Wisent).
Experimental in vitro protocol and cytokine stimulation
Confluent HUVEC monolayers were allocated to one of
the six following experimental groups: (1) control, (2) vehicle
treated (0.25% DMSO corresponding to CORM-2 and ODQ
concentration used in the experiments), (3) inactivated
CORM-2 (100mmol/l), (4) CORM-2 treated (100mmol/l),
(5) ODQ treated (10mmol/l), and (6) ODQ (10mmol/l)
followed by CORM-2 (100mmol/l). All experiments were
performed in culture medium M199 supplemented with 5%
fetal calf serum. Incubation conditions and temperature were
kept constant throughout the experimental period. According
to the experimental distribution, HUVECs were first treated
with ODQ dissolved in DMSO (10mmol/l final concentration,
groups 5 and 6), DMSO alone (0.25%, groups 2, 3, and 4), or
M199 (group 1) for 30 min. Medium was removed and the
cells were washed with M199. Then, HUVECs were treated
with inactive CORM-2 dissolved in DMSO (100mmol/l, group
3), active CORM-2 (100mmol/l, groups 4 and 5), DMSO alone
(0.25%, groups 2 and 6), or M199 (group 1) for 1 h. Medium
was removed and the cells were washed with M199.
In this study, we used an in vitro model of cytokine
stimulation as an in vitro reproduction of the post-transplant
environment. Confluent HUVEC monolayers were exposed
to a cytokine mix of TNF-a (10 ng/ml) and interferon-g
(10 ng/ml) prepared in M199 with 5% fetal calf serum. Cells
were exposed for 1, 2, or 4 h depending on the end point
assessed. The cytokine-containing medium was removed and
cells were washed with PBS.
Measurement of ROS
ROS production (NADPH oxidase-dependent production of
O2
) in HUVECs was assessed using the lucigenin-enhanced
chemiluminescence method as described previously.51,52
Briefly, following the treatments, HUVECs were scraped
and sonicated in a buffer containing 20 mmol/l KH2PO4
(Sigma), pH 7.0, 1 mmol/l ethylene glycol tetraacetic acid
(Sigma), 1 mmol/l phenylmethylsulfonyl fluoride (Calbiochem,
Gibbstown, NJ), 1mg/ml aprotinin (Calbiochem), 1 mg/ml
leupeptin (Sigma) and 1 mg/ml pepstatin (Sigma)) at a 30%
power output for 10 s. Protein concentration was measured
using the Bio-Rad (Hercules, CA) protein assay reagent. The
HUVEC homogenates (50 ml containing 50–100 mg protein)
were incubated with 125 ml of assay buffer (50 mmol/l
phosphate buffer, pH 7.0, 1 mmol/l EGTA, 150 mmol/l
sucrose (Sigma)) and 25 ml of 1 mmol/l NADPH in a
Lumitrac 96-well plate (Greiner Bio-One, Mississauga,
ON, Canada) at 37 1C for 20 min. Subsequently, lucigenin
(5 mmol/l; Sigma) was added to the samples and photon
emission was continuously recorded for 5 min at 37 1C in a
luminometer (Victor-3 Multilabel Counter, Perkin Elmers,
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Waltham, MA). NADPH oxidase-dependent production of
O2
 was expressed as relative chemiluminescence (light)
units/mg protein.
Western blot
Activation of NF-kB was assessed by the means of
degradation of its IkB. To this end, HUVECs grown in six-
well cell culture plates were washed following various experi-
mental treatments with PBS containing protease inhibitors
(Sigma) and lysed in a hot electrophoresis sample-loading
buffer. Sample protein concentration was determined
using detergent-compatible protein assay (Bio-Rad). Equal
amounts of protein (100 mg) were electrophoresed on 7%
SDS-polyacrylamide gel electrophoresis. Subsequently, the
proteins were transferred on to polyvirylidine difluoride
membrane and interacted with rabbit anti-IkB antibody
(Santa Cruz, CA). Antibody binding was visualized by
enhanced chemiluminescence assay using secondary goat-
anti-rabbit horseradish peroxidase-conjugated antibody
(Santa Cruz, CA).
Reverse transcription-PCR
Total cellular RNA was extracted from HUVECs by the
Tri-Zol reagent (Invitrogen, Burlington, ON, Canada). First-
strand complementary DNA was synthesized from 3 mg of
total RNA using the SuperScript II Reverse Transcriptase kit
(Invitrogen) according to the manufacturer’s protocol. The
complementary DNA was amplified with template-specific
primers and SYBR green master mix (Bio-Rad) using the
Mini Opticon real-time PCR system. The primers used for
real-time PCR were as follows: for b-actin, forward primer:
5-CTGGAACGGTGAAGCTGACA-30 and reverse primer: 50-
AAGGGACTTCCTGTAACAATGCA-30; for ICAM-1 forward
primer: 50-AAGGTCACCAGGTACAGTTG-30 and reverse
primer: 50-AACCTGTGAACCATTACCAG-30; and for E-
selectin forward primer: 50-ACGGTGAATGTGTAGAGACC-30
and reverse primer: 50-TGTAGCTGAAGTTTCCCAGT-30.
Reactions were incubated at 95 1C for 10 min, and PCR
amplification was performed with 35 cycles of 10 s at 95 1C,
20 s at 55 1C, and 1 min at 72 1C. Subsequently, the melting
curves were examined to ensure the homogeneity of the PCR
products. The relative quantities of genes of interest norma-
lized to b-actin were analyzed by GENEX software (Bio-Rad).
Cell ELISA
For assessment of adhesion molecule ICAM-1 and E-Selectin
surface expression levels, cell ELISA was performed on HUVECs
grown in 96-well cell culture plates (BD Falcon-BD Biosciences,
Mississauga, ON, Canada) as described by our group.29
HUVECs were fixed in 3% paraformaldehyde for 30 min. The
cells were then washed with PBS and incubated with the
primary mouse anti-human ICAM-1 (Santa Cruz Biotechno-
logy, Santa Cruz, CA), and E-selectin (R&D Systems, Burlington,
ON, Canada) monoclonal antibodies at a concentration
of 10 mg/ml for 1 h at room temperature. Anti-ICAM-1
and anti-E-selectin antibodies binding to HUVECs were
quantitated spectrophotometrically at 450 nm wavelength
(Bio-Rad-680 microplate reader) by the use of mouse
extravidin-peroxidase staining kit (Sigma) and 3,30,5,
50-tetramethylbenzidine (Sigma) as peroxidase substrate.
PMN adhesion assay
Human neutrophilic PMN cells were isolated from the
venous blood of healthy adults using standard dextran
sedimentation and gradient separation on Histopaque-1077
(Sigma).29 For the adhesion assay, PMN cells were sus-
pended in PBS and radiolabeled by incubating the cells at
5 107 cells/ml with 50 mCi Na51CrO4/ml PMN suspension
at 37 1C for 60 min. The cells were then washed with cold PBS
to remove unincorporated radioactivity. 51Cr-labeled PMN
(5 105/well) cells were added to HUVEC monolayers and
incubated for 30 min at 37 1C The percentage of added PMN
that remained adherent after a wash procedure was quantified
as follows: %PMN adherence¼ lysate (c.p.m.)/(supernatant
(c.p.m.)þwash (c.p.m.)þ lysate (c.p.m.)), in which c.p.m. is
counts per minute.29,53
Statistical analysis
All the values are presented as means±s.e. Statistical analysis
of the in vitro data was performed by one-way analysis of
variance, and differences were considered to be significant if
the P-value was o0.05 based on Newman–Keuls Multiple
Comparison Test. Animal survival analysis was performed
with one-way analysis of variance for comparison between
experimental groups. Histopathology findings were com-
pared using the Mann–Whitney U-test. Again, differences in
P-valueso0.05 were considered significant. All analyses were
performed using the Prism software version 5.0a (GraphPad
Software, San Diego, CA).
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